Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
129 hedge funds and large institutions have $324M invested in Mersana Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 49 increasing their positions, 37 reducing their positions, and 15 closing their positions.
47% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 15
32% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 37
6% more funds holding
Funds holding: 122 → 129 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.01% less ownership
Funds ownership: 3.9% → 3.89% (-0.01%)
26% less capital invested
Capital invested by funds: $437M → $324M (-$113M)
89% less call options, than puts
Call options by funds: $42K | Put options by funds: $372K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$19.8M |
| 2 |
O
OrbiMed
New York
|
+$8.88M |
| 3 |
D.E. Shaw & Co
New York
|
+$6.76M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$5.41M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$5.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$21.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$13.4M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.68M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.09M |
| 5 |
Rafferty Asset Management
New York
|
-$1.73M |
MRSN Hedge Fund Activity: Q1 2022 in Review
129 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q1 2022, worth a combined $324M — down 26% from $437M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new MRSN positions and 15 closed out — a net gain of 7 holders — while 49 added to existing stakes and 37 trimmed.
The largest buyer was Millennium Management, adding an estimated $19.8M. The largest seller was Wellington Management Group, cutting an estimated $21.2M.
- 129 institutional investors held Mersana Therapeutics (MRSN) as of Q1 2022, up from 122 in Q4 2021.
- Funds reported $324M of Mersana Therapeutics stock for Q1 2022, down 26% quarter-over-quarter.
- 22 funds opened new Mersana Therapeutics positions in Q1 2022 and 15 closed out, a net change of +7 holders.
- The largest Mersana Therapeutics buyer in Q1 2022 was Millennium Management, an estimated $19.8M added.
- The largest Mersana Therapeutics seller in Q1 2022 was Wellington Management Group, an estimated $21.2M sold.
Based on aggregated 13F filings for Q1 2022.